Evidence map›Paper›PMID 35663378›Full record

ArticleBone reports2022

Growth hormone therapy in HHRH.

Guido Filler, Clara Schott, Fabio Rosario Salerno, Andrea Ens, Christopher William McIntyre, Maria Esther Díaz González de Ferris, Robert Stein

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Guido FillerDepartments of Pediatrics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
Clara SchottMedical Sciences, University of Western Ontario, Canada.
Fabio Rosario SalernoBiophysics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
Andrea EnsDepartments of Pediatrics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
Christopher William McIntyreDepartments of Pediatrics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
Maria Esther Díaz González de FerrisUniversity of North Carolina at Chapel Hill, Department of Pediatrics, Chapel Hill, NC, USA.
Robert SteinDepartments of Pediatrics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
Western University · CAUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) ( Methods: We describe Results: The patient had chronic bone pain, hypophosphatemia (0.65 mmol/L[reference interval 1.1-1.9]), pathological fractures and medullary nephrocalcinosis/hypercalciuria (urinary calcium/creatinine ratio 1.66 mol/mmol[<0.6]). TmP/GFR was 0.65 mmol/L[0.97-1.64]; 1,25(OH) Conclusions: The addition of rhGH, Fluconazole and salt restriction to phosphate/potassium supplementation improved the conventional therapy. Larger studies are needed to confirm our findings.

Indexed as

23Na MRIHereditary hypophosphatemic rickets with hypercalciuriaRecombinant human growth hormoneSodium phosphate cotransporterTubular phosphate wasting

Identifiers

PMID35663378
PMCPMC9156862
OpenAlexW4280502969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.